Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CO-1686: Preliminary Phase I/II data

Clovis reported preliminary response data from 6 previously treated patients with metastatic or unresectable recurrent NSCLC and a documented EGFR mutation in the dose-escalation Phase I portion of an open-label, U.S. and French Phase I/II trial evaluating once- and twice-daily doses of

Read the full 422 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers